Publications

Antimicrobial Activity of Dalbavancin Tested against Gram-Positive Organisms Isolated from Patients with Infective Endocarditis in United States and European Medical Centers. Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1081

Comparative Activity of Plazomicin and Other Aminoglycosides against Enterobacteriaceae Isolates from Various Infection Sources from Hospitalized Patients in the United States. Lead author: M Castanheira, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1345

Efficacy of Omadacycline against Molecularly Characterized Gram-Positive and Gram-Negative Pathogens Causing Infections in the Phase 3 CABP and ABSSSI Clinical Trials. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1364

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) Gram-Negative Isolates from Patients with Pneumonia in US Medical Centers. Lead author: SJR Arends, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1485

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections: Results from the International Network for Optimal Resistance Monitoring (INFORM) Program. Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1523

Omadacycline In Vitro Activity against a Molecularly Characterized Collection of Clinical Isolates with Known Tetracycline Resistance Mechanisms. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1377

Global Surveillance: Susceptibility of Ceftolozane-Tazobactam against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa Isolates Collected from Bloodstream Infections in the United States from 2015-2017. Lead author: SJR Arends, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1047

Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program. Lead author: HS Sader, presented at ID Week 2018, October 3-7, San Francisco, CA, USA.
#1000

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bloodstream Infections in United States Medical Centers (2015-2017). Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA USA
#1004

Analyses of a ceftazidime-avibactam-resistant Citrobacter freundii isolate carrying bla_kpc-2 reveals a heterogenous population and reversible genotype. by Castanheira M, Arends SJR, Davis AP, Woosley LN, Bhalodi AA and MacVane SH published in MSphere. 2018; 3 (5): e00408

Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M. Antimicrob. Agents Chemother.: in press, 2018.

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. by Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M and Jain R. published in Infect Drug Resist. 2018; 2018 (11): 1499-1510

Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. by Castanheira M, Deshpande LM, Woosley LN, Serio AW, Krause KM and Flamm RK. published in J. Antimicrob. Chemother.: in press, 2018.

Analysis of Oritavancin In Vitro Activity against Enterococcal Isolates from US Medical Centers and Resistant Subsets. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal
#116

Activity of Meropenem-Vaborbactam and Comparator Agents against Multidrug-Resistant Enterobacteriaceae Isolates from the United States Analyzed by Site of Infection. Lead author: M Castanheira, presented at ESMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#117

Spectrum of Activity of RX-P2382, a Novel Class of Bacterial Ribosome Inhibitor. Lead author: D Shortridge, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#46

Tedizolid In Vitro Activity against a Contemporary Challenge Collection of Multidrug-Resistant Enterococcal Clinical Isolates. Lead author: CG Carvalhaes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#111

In Vitro Activity Evaluation of a Next-Generation Polymyxin, SPR206, against Non-Fermentative Gram-Negative Bacilli Responsible for Human Infections. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#80

Activity of an Investigational Polymyxin-B-Like Compound (SPR206) against a Set of Enterobacteriaceae Organisms Responsible for Human Infections. Lead author: RE Mendes, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#81

The Role of Whole Genome Sequencing on Post-Marketing Surveillance Programs: Results of the INFORM Surveillance Program for Ceftazidime-Avibactam in the United States. Lead author: H Sader, presented at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, September 4-7, 2018, Lisbon, Portugal
#107

Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. by Sader HS, Flamm RK, Dale GE, Rhomberg PR and Castanheira M published in J Antimicrob Chemother. 2018; 73: 2400-2404

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. by Pfaller MA, Mendes RE, Duncan LR, Flamm RK and Sader HS. published in J. Antimicrob. Chemother. 2018; 73 (10) 2748-2756

Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). by Sader HS, Castanheira M, Mendes RE and Flamm RK published in J. Antimicrob. Chemother.: in press, 2018.

Delafloxacin in vitro broth microdilution and disk diffusion antimicrobial susceptibility testing guidelines: Susceptibility breakpoint criteria and quality control ranges for an expanded spectrum anionic fluoroquinolone. by Pfaller MA, Flamm RK, McCurdy SP, Pillar CM, Shortridge D and Jones RN published in J. Clin. Microbiol. 2018; 56 (8): e00339

Disruption of mgrB and Alterations on pmrB Are Most Common Resistance Mechanisms among Colistin-Resistance among Klebsiella pneumoniae from a Global Surveillance Program. Lead author: M Castanheira, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-467

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-393

Global Trends in Prevalence and Diversity of Carbapenemases Carrying Enterobacteriaceae Identified through SENTRY Antimicrobial Surveillance Program. Lead author: LM Deshpande, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-404https://www.jmilabs.com/wp-admin/post.php?post=6561&action=edit#

Antimicrobial Activity of the Novel Siderophore Cehpalosporin GT-1 Tested Alone and Combined with the β-Lactamase Inhibitor GT-055 against Molecularly Characterized Enterobacteriaceae Clinical Isolates. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-571

In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Multidrug-Resistant Streptococcus pneumoniae (2014-2017): Results from the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-397

Antimicrobial Activity Assessment of Tebipenem (SPR859) against an Isolate Collection Causing Urinary Tract Infections. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-560

Antimicrobial Activity of Ceftobiprole When Tested against Gram-Positive Cocci Causing Serious Infections (2016-2017): Endocarditis, Diabetic Foot, and Bone/Joint Infections. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-581

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by United States Census Divisions: Results from the 2017 INFORM Program. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA.
# Sunday-388

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Isolates Collected from Hematology or Oncology Patients in Europe during 2011-2017 as Part of a Global Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-394

Antimicrobial Activity of Tebipenem (SPR859) against a Global Challenge Set of Enterobacteriaceae Isolates. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-558

Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) Gram-Negative Isolates from Intensive Care Unit Patients with Pneumonia in US Medical Centers. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-392

The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. Lead author: DJ Diekema, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-400

Characterization of Variant mcr-1.11 and Prevalence of mcr Genes among Escherichia coli and Klebsiella pneumonia Clinical Isolates Collected Worldwide. Lead author: LM Deshpande, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-468

Antimicrobial Activity of GT-1, a Novel Siderophore Cephalosprin, Tested against Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter spp. Isolates. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Sunday-577

Fosfomycin Activity against Gram-Negative Isolates from Eastern Europe Collected by the SENTRY Antimicrobial Surveillance Program. Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-632

Omadacycline In Vitro Activity against Skin and Skin Structure, Respiratory, and Urinary Tract Pathogens Collected from the United States and Europe During the 2017 SENTRY Surveillance Program. Lead author: MD Huband. Presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-627

Activity of Fosfomycin against Gram-Negative Baseline Bacterial Isolates from Patients in a Phase 3 Complicated Urinary Tract Infection Trial (ZEUS). Lead author: D Shortridge, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-633

Molecular Characterization of Clinical Trial Isolates Exhibiting Increased MIC Results during Fosfomycin (ZTI-01) Treatment in a Phase 2/3 Clinical Trial for Complicated Urinary Tract Infections (ZEUS). Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-637

Activity of Plazomicin and Comparator Agents Tested against Contemporary Clinical Isolates Collected Worldwide. Lead author: M Castanheira, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-645

Distribution of β-Lactamase Resistance Genes and Lineage Background in Clinical Isolates Producing Extended-Spectrum β-Lactamases by High-Resolution Genomic Analysis. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-426

Correlation between Broth Microdilution and Disk Diffusion Methods Results When Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Molecular Characterization of Isolates with Elevated Ceftaroline MIC Results. Lead author: HS Sader, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-214

Molecular Characterization of Resistance Mechanisms Associated with Pleuromutilins Among Gram-Positive Clinical Isolates From the Worldwide SENTRY Surveillance Studies for Lefamulin. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Saturday-642

Current Assessment of Oritavancin Activity against Multidrug-Resistant Enterococcal Clinical Isolates. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-452

In Vitro Activity of Tedizolid and Comparator Agents Tested against Gram-Positive Isolates Causing Serious Infections in Hospitalized Patients in the United States and Europe. Lead author: RE Mendes, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-453

In Vitro Activity of a Novel Extended-Spectrum β-Lactamase Inhibitor, AAI101, in Combination with Cefepime, against Enterobacteriaceae Isolates Collected during 2016. Lead author: MD Huband, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-601

Activity of Telavancin against a Contemporary Collection of Staphylococcus aureus Clinical Isolates from All 9 US Census Bureau Divisions. Lead author: LR Duncan, presented at ASM Microbe 2018, June 7-11, Atlanta, GA, USA
# Friday-416